© 2021 MJH Life Sciences and OncLive. All rights reserved.
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2021 MJH Life Sciences™ and OncLive. All rights reserved.
January 22, 2021
Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.
January 13, 2021
Early detection, personalized treatment approaches, and increased situational awareness have improved cancer patient survival rates. Ongoing dialogue among leading experts can only improve patient outcomes and advance the field of multiple myeloma.
November 04, 2020
Unprecedented treatment advances have been made during the last decade for patients with advanced melanoma.
November 03, 2020
Kari B. Wisinski, MD, discusses the evolving roles of immunotherapy, ADCs, and PARP inhibitors in triple negative breast cancer.
October 22, 2020
Parameswaran Hari, MD, MRCP, discusses key data that has read out in relapsed/refractory multiple myeloma, exciting agents generating excitement, and the role of minimal residual disease.
October 19, 2020
Elisavet Paplomata, MD, discusses the role of tucatinib in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.